14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SANA vs ERAS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ERAS Overall Winner
6-Pillar Tally: SANA 0 – 4 ERAS (2 Tie)
Matrix Metrics: SANA 2 – 3 ERAS
As of Nov 16, 2026, Erasca, Inc. (ERAS) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SANA carries a Unified Composite Score of 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin), whereas ERAS carries 37.5/100 (SELL) at $15.11 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While SANA currently prints a higher short-term Unified Composite Score (44.3/100 HOLD vs. ERAS 37.5/100 SELL), ERAS captures the overall institutional head-to-head verdict (3–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile ERAS is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs ERAS. Trailing 12-month operating profitability (SANA 0.0% vs ERAS 0.0%) and valuation multiples (SANA N/M vs ERAS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $5.5B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SANA vs ERAS Key Questions & Quantitative Answers
As of Nov 16, 2026, Erasca, Inc. (ERAS) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SANA carries a Unified Composite Score of 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin), whereas ERAS carries 37.5/100 (SELL) at $15.11 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SANA currently prints a higher short-term Unified Composite Score (44.3/100 HOLD vs. ERAS 37.5/100 SELL), ERAS captures the overall institutional head-to-head verdict (3–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile ERAS is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ERAS leads the Growth & Scale pillar: SANA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ERAS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SANA generates N/A in USD-normalized revenue versus N/A for ERAS. In operating R&D and SG&A reinvestment, SANA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ERAS.
SANA and ERAS trade at balanced relative valuation multiples. SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ERAS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SANA (-79.5% ROE) versus ERAS (-48.7% ROE) capital efficiency.
In options market volatility and institutional positioning, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk). By comparison, ERAS carries 84.2% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 80% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.